Status In progress
Process STA
ID number 1055

Provisional Schedule

Committee meeting: 1 23 November 2017
Expected publication 23 May 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Gilead Sciences
Others Department of Health
  NHS England
  NHS Oxfordshire CCG
  Welsh Government
Patient carer groups Haemophilia Society
  Hepatitis C Trust
Professional groups British Association for Sexual Health and HIV
  British Association for the Study of the Liver
  British HIV Association
  British Infection Association
  British Society of Gastroenterology
  Royal College of Pathologists
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Comparator companies Abbvie (ombitasvir-paritaprevir-ritonavir, and dasabuvir)
  Bristol-Myers Squibb (daclatasvir) - CAU not returned, not participating
  Gilead Sciences (sofosbuvir, ledipasvir-sofosbuvir, sofosbuvir-velpatasvir)
  Meda Pharmaceuticals (ribavirin) - CAU not returned, not participating
  Merck Sharp & Dohme (elbasvirgrazoprevir,
  peginterferon alfa 2b, ribavirin)
  Mylan UK (ribavirin) - CAU not returned, not participating
  Roche Products (peginterferon alfa 2a, ribavirin) - CAU not returned, not participating
  Teva UK (ribavirin) - CAU not returned, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Hepato-Biliary Group

Timeline

Key events during the development of the guidance:

Date Update
27 June 2017 Invitation to participate
21 April 2017 In progress, Topic referred
21 April 2017 Referral
03 January 2017 - 31 January 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance